apraglutide

Peptide

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Latest reported trial: STARS (NCT04627025) · Phase 3 · met primary endpoint · grade pending

Company guidance: data expected in 2029 (NCT04627025; Ironwood Pharmaceuticals, 5 Nov 2026). “Subject to the results of the STARS-2 clinical trial, Ironwood plans to file for regulatory approval in 2029 and aims to identify” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Short Bowel Syndrome
NCT05018286 · VectivBio AG
2021-07-13 – 2027-10-30 · Short Bowel Syndrome
What this study did
Phase 2 (2)
Short Bowel Syndrome
NCT04964986 · VectivBio AG
2021-06-14 – 2023-06-06 · Short Bowel Syndrome
What this study did
Other / comorbidity
NCT05415410 · VectivBio AG
2022-05-25 – 2024-12-17 · GVHD
What this study did
Phase 1 (4)
Other / comorbidity
NCT06002555 · VectivBio AG
2023-05-23 – 2023-09-22 · Healthy Subjects
What this study did
NCT05995704 · VectivBio AG
2023-03-02 – 2023-07-24 · Healthy Subjects
What this study did
NCT05706623 · VectivBio AG
2023-01-30 – 2023-04-04 · Hepatic Impairment
What this study did
NCT04699032 · VectivBio AG
2020-12-08 – 2021-07-05 · Chronic Kidney Disease
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Short Bowel Syndrome: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Apraglutide: this drugPhase 3PeptideGLP-2 receptornot yet gradedNo reviewed efficacy summary in this indication
Teduglutide (Gattex)ApprovedPeptideGLP-2 receptorPartial signal
NCT02682381: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants
NCT00798967: Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects
Crofelemer (Mytesi)Phase 2Small moleculeChloride channel (intestinal epithelium)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow apraglutide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 3Short Bowel SyndromeActive not recruiting
Est. primary completion 2027-10-30 · NCT05018286 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
Phase 3Short Bowel SyndromeRecruiting
Est. primary completion 2028-10 · NCT07742735 · CT.gov ↗
What to watch

See the full readout calendar ↗